| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
GLENMARK PHARMACEUTICALS LTD. (BSE: 532296)
532296 Technical Analysis
5
| As on 23rd Apr 2024 532296 SHARE Price closed @ 1034.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 806.25 & Strong Buy for SHORT-TERM with Stoploss of 938.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
532296SHARE Price
| Open | 1035.65 | Change | Price | % |
| High | 1043.15 | 1 Day | -6.55 | -0.63 |
| Low | 1018.20 | 1 Week | -25.40 | -2.40 |
| Close | 1034.20 | 1 Month | 83.50 | 8.78 |
| Volume | 39997 | 1 Year | 522.80 | 102.23 |
| 52 Week High 1068.00 | 52 Week Low 514.55 | ||||
BSE INDIA Most Active Stocks
| 532822 | 14.39 | 11.64% |
| 512149 | 0.91 | -4.21% |
| 532648 | 25.66 | 1.79% |
| 532775 | 1.73 | -1.14% |
| 517001 | 0.09 | 12.50% |
| 530557 | 0.73 | 1.39% |
| 511389 | 7.25 | -2.42% |
| 534690 | 7.65 | 4.79% |
| 532667 | 41.80 | 2.28% |
| 512499 | 0.49 | -2.00% |
BSE INDIA Top Gainers Stocks
BSE INDIA Top Losers Stocks
| 532296 Daily Charts |
532296 Intraday Charts |
Whats New @ Bazaartrend |
532296 Free Analysis |
|
|
532296 Important Levels Intraday
| RESISTANCE | 1082.28 |
| RESISTANCE | 1066.86 |
| RESISTANCE | 1057.33 |
| RESISTANCE | 1047.80 |
| SUPPORT | 1020.60 |
| SUPPORT | 1011.07 |
| SUPPORT | 1001.54 |
| SUPPORT | 986.12 |
532296 Target April 2024
| 4th UP Target | 1131.99 |
| 3rd UP Target | 1076.03 |
| 2nd UP Target | 1041.44 |
| 1st UP Target | 1006.85 |
| 1st DOWN Target | 908.15 |
| 2nd DOWN Target | 873.56 |
| 3rd DOWN Target | 838.97 |
| 4th DOWN Target | 783.01 |
532296 Weekly Target
| 4th UP Target | 1110.13 |
| 3rd UP Target | 1082.88 |
| 2nd UP Target | 1066.03 |
| 1st UP Target | 1049.18 |
| 1st DOWN Target | 1001.12 |
| 2nd DOWN Target | 984.27 |
| 3rd DOWN Target | 967.42 |
| 4th DOWN Target | 940.17 |
532296 Target2024
| 4th UP Target | 1836.1 |
| 3rd UP Target | 1521.13 |
| 2nd UP Target | 1326.45 |
| 1st UP Target | 1131.76 |
| 1st DOWN Target | 576.24 |
| 2nd DOWN Target | 381.55 |
| 3rd DOWN Target | 186.87 |
| 4th DOWN Target | -128.1 |
GLENMARK PHARMACEUTICALS LTD. ( BSE INDIA Symbol : 532296 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
532296 Business Profile
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830, an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISC 17536, an oral transient receptor potential ankyrin-1 antagonist, which has completed Phase 2a clinical trial for the treatment of diabetic peripheral neuropathy; ISB 1302, a HER2 X CD3 beat bispecific antibody, which is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; ISC XXXXX, an HPK1 inhibitor for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma t for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was founded in 1977 and is based in Mumbai, India. Address: Glenmark House, Mumbai, India, 400099
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service